argenx launches tender offer for Forte Biosciences at $77 a share

* argenx launched a cash tender offer for all outstanding Forte Biosciences shares at USD 77 per share. * The offer follows a July 26, 2026 merger agreement between the companies. * The tender offer is set to expire Aug. 26, 2026 at 11:59 p.m. ET, unless extended or terminated earlier. * Closing conditions include a majority of shares tendered, measured as more than 50% of shares outstanding. * The deal is not subject to a financing condition; a second-step merger would make Forte a wholly owned argenx unit.

Tender offer for Forte Biosciences

Related News

Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer

Solventum Corporation <SOLV.N>: Wedbush Raises Target Price to $101 From $94

Andy O'Brien, the insider poised to lead ConocoPhillips

Sources

argenx launches tender offer for Forte Biosciences at $77 a share

Whitehawk Therapeutics Q2 net loss narrows

Oklo says Groves isotope test reactor reaches first criticality in Texas